上海、台北、舊金山– 2023年4月12日
漢康生技（HanchorBio Inc.）是一家處於臨床開發階段的腫瘤免疫領域新藥研發的全球性生物科技公司，於2023年3月29日在台北總部成功舉辦了科學顧問委員會（SAB）會議。本次會議集結了世界享譽盛名的專家教授以及漢康生技的部分董事會成員，包括：
l 陳明義教授，MD., PhD.，美國德州大學西南醫學中心病理學教授
l 李子海教授，MD., PhD.，俄亥俄州立大學James綜合腫瘤中心Pelotonia腫瘤免疫研究所教授、創始主任
l 鄒偉平教授，MD., PhD.，密西根大學腫瘤免疫和免疫治療卓越中心主任
l 劉世高博士，漢康生技創辦人、董事長暨執行長
l Rosemary Mazanet, MD., PhD.，（漢康董事會成員）Panacea Venture創業合夥人
l 陸英明博士，MBA., PhD., CCRA.，（漢康董事會成員）專家顧問
l 卓宗顯博士，漢康生技總經理兼首席科學官
l 曾琪鈴博士，漢康生技研發副總裁
SAB科學顧問委員會對於漢康生技策略發展，扮演一個關鍵決策的角色，SAB委員會在研發方面提供科學和臨床見解，並指導研發團隊進一步加強基於FBDB™創新技術的產品研發進度。
在本次SAB科學會議期間，討論了HCB101的最新研究進展，HCB101為一種基於IgG4-Fc全新工程化改構的SIRPα融合蛋白。HCB101作為巨噬細胞的受體誘餌，通過阻斷SIRPα-CD47之間“不要吃我”的信號通路來觸發巨噬細胞吞噬腫瘤細胞的活動。基於大量的體外和體內臨床前研究資料，HCB101有可能是一個比目前正在進行臨床開發階段的CD47抗體更安全且更有效的產品。此外，RNA熱圖結果表明，HCB101和莫洛利單抗（抗CD47單克隆抗體）之間具有顯著不同的基因表達圖譜。在HCB101堅實的科學研究基礎之上，研發團隊進一步介紹了通過工程化改構的方式接入多種免疫調節因數，如PD-L1和其它基於免疫檢查點抑制劑的受體誘餌和細胞因數或細胞因數誘餌等，以解決目前抗PD-1/L1腫瘤免疫療法的耐藥性問題。
SAB成員高不僅讚揚了漢康生技團隊在臨床前環境中對HCB101的安全性和有效性進行深入和全面的論證過程中所取得的成就，並且再次肯定了提交給SAB的四個項目的科學合理性和技術可行性。同時，SAB的成員還認可了三臂FBDBs™（基於Fc設計的生物製劑）在突破性和變革性方面的巨大潛力，因為它們不僅是一流的生物製劑，而且代表了一類具有多種免疫調節功能的新穎獨特的模式。
關於漢康生技
漢康生技的總部位於台北、上海和三藩市灣區，是一家專注於免疫腫瘤學的全球臨床階段生物技術公司，公司的領導團隊包括了在生物製劑研發與全球藥物開發方面擁有豐富經驗的科學家和管理人員。這群專家在開發全新癌症療法方面，已有顯著的研發成果。
漢康生技研發團隊以其專有的“Fc基礎生物製劑（FBDB™）”平台技術，致力於重新啟動免疫系統以對抗疾病，使具有多種多靶點模式的獨特生物製劑能夠釋放先天性和適應性免疫，以克服當前抗PD1 / L1免疫療法的挑戰。通過FBDB™平台開發的生物產品已經成功地在多個腫瘤動物模型的體內實驗中得到了概念驗證數據。通過在研發階段對多功能創新分子構型上的突破、以及在工藝開發階段對生產工藝的優化與改進，漢康生技立志於以創新生物藥物來解決腫瘤免疫治療領域中未被滿足的臨床需求。
👉如需了解更多信息，敬請訪問公司官網：www.HanchorBio.com
👉或在LinkedIn上關注我們：www.linkedin.com/company/hanchorbio-inc
HanchorBio Completes the Face-to-Face Scientific Advisory Board Meeting
SHANGHAI, TAIPEI, and SAN FRANCISCO, April 11, 2023 – HanchorBio Inc., a global
clinical-stage biotechnology company developing innovative immuno-medicines, completed a
face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023, in Taipei, Taiwan with
world-renowned professors and few Board of Director (BOD) members. The attendees included:
• Mingyi Chen, MD., PhD., (Chairman of SAB) Professor of Pathology at the UT Southwestern
Medical Center
• Zihai Li, MD., PhD., Professor and Founding Director of the Pelotonia Institute for Immuno-
Oncology at the Ohio State University James Comprehensive Cancer Center
• Weiping Zou, MD., PhD., Charles B. de Nancrede Professor and Director of the Center of
Excellence for Cancer Immunology and Immunotherapy at the University of Michigan School
of Medicine
• Rosemary Mazanet, MD., PhD., (member of the BOD) Venture Partner of Panacea Venture
• Alvin Luk, MBA., PhD., CCRA., (member of the BOD) independent consultant
• Sean Juo, PhD., President and Chief Scientific Officer of HanchorBio
• Chi-Ling Tseng, PhD., Vice President of Research of HanchorBio
• Scott Liu, PhD., Founder, Chairman, and Chief Executive Officer of Hanchorbio
The Scientific Advisory Board is a critical decision for HanchorBio’s strategic development, and
the board provides scientific and clinical insights and guidance in research and development to
further strengthen the product pipeline based on the Company’s innovative technology of Fc-based
designer biologics (FBDB™).
HanchorBio Completes the Face-to-Face Scientific Advisory Board Meeting
During the SAB meeting, the Company reviewed its lead product, HCB101, which is an
engineered SIRPα protein fused to the Fc region of IgG4. HCB101 triggers phagocytosis activity
of the macrophages by blocking the “do not eat me” SIRPα-CD47 signaling pathway between
macrophages and tumor cells as a decoy receptor of the macrophage. Based on the extensive invitro
and in-vivo pre-clinical data, HCB101 is potentially a safer and more potent alternative than
the anti-CD47 monoclonal antibodies currently in clinical trials. Furthermore, RNA heat map
experiments demonstrated distinct gene expression profiles in comparison between HCB101 and
Magrolimab (anti-CD47 monoclonal antibody). Based on the solid scientific foundation of
HCB101, the Company further revealed the additional arms (being added to the Fc backbone) such
as PD-L1 and other immune-checkpoint-inhibitor-based ligand traps and cytokines or cytokine
traps to combat against resistance to current anti-PD1/L1 immunotherapies.
The SAB members not only complimented the team on the accomplishments of the in-depth and
comprehensive demonstration of the safety and efficacy of HCB101 in preclinical settings, but
also reaffirmed the scientific soundness and technical feasibility of the four projects presented to
the SAB. The members of the SAB also recognized the breakthrough and transformational
potentials of the 3-arm FBDBs as they are not only first-in-class biologics, but also represent a
novel and unique class of modality with multiple immune-modulation functionalities.
About HanchorBio
Based in Taipei, Shanghai, and San Francisco Bay Area, HanchorBio is a global clinical-stage
biotechnology company focusing on immuno-oncology. The Company is led by an experienced
team of pharmaceutical industry veterans with proven track-record of success in biologics
discovery and global development to rewrite cancer therapies. Committed to reactivating the
immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™)
platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and
adaptive immunity to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™
platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By
making breakthroughs in multi-functional innovative molecular configurations in
R&D and improving the manufacturing process in CMC, HanchorBio develops
transformative medicines to address unmet medical needs.
For more information, please visit: www.HanchorBio.com
or follow us on LinkedIN at www.linkedin.com/company/hanchorbio-inc